Aga (2011) American gastroenterological association medical position statement on the management of Barrett’s esophagus. Gastroenterology 140:1084–1091
Article
Google Scholar
Barlesi F, Drilon A, De Braud F et al (2019) Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): integrated analysis of ALKA-372-001, STARTRK‑1 and STARTRK‑2. Ann Oncol 30:ii48–ii49
Article
Google Scholar
Bedard PL, Hyman DM, Davids MS et al (2020) Small molecules, big impact: 20 years of targeted therapy in oncology. Lancet 395:1078–1088
CAS
Article
Google Scholar
Coleman HG, Bhat S, Murray LJ et al (2011) Increasing incidence of Barrett’s oesophagus: a population-based study. Eur J Epidemiol 26:739–745
Article
Google Scholar
Corley DA, Kubo A, Levin TR et al (2009) Race, ethnicity, sex and temporal differences in Barrett’s oesophagus diagnosis: a large community-based study, 1994–2006. Gut 58:182–188
CAS
Article
Google Scholar
Drilon A, Laetsch TW, Kummar S et al (2018) Efficacy of larotrectinib in TRK fusion—positive cancers in adults and children. N Engl J Med 378:731–739
CAS
Article
Google Scholar
Falk GW (2002) Barrett’s esophagus. Gastroenterology 122:1569–1591
Article
Google Scholar
Horak P, Heining C, Kreutzfeldt S et al (2021) Comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers. Cancer Discov 11(11):2780–2795. https://doi.org/10.1158/2159-8290.CD-21-0126
Horak P, Klink B, Heining C et al (2017) Precision oncology based on omics data: the NCT Heidelberg experience. Int J Cancer 141:877–886
CAS
Article
Google Scholar
Kreutzfeldt S, Apostolidis L, Oles M et al (2019) Clinical outcome of personalised treatment guided by genome and transcriptome sequencing in patients with neuroendocrine neoplasms: updated results from the German NCT/DKTK MASTER trial. Ann Oncol 30:vii6
Article
Google Scholar
Larson KL, Huang B, Weiss HL et al (2021) Clinical outcomes of molecular tumor boards: a systematic review. JCO Precis Oncol 9(5):PO.20.00495. https://doi.org/10.1200/PO.20.00495
Article
Google Scholar
Leichsenring J, Horak P, Kreutzfeldt S et al (2019) Variant classification in precision oncology. Int J Cancer 145:2996–3010
CAS
Article
Google Scholar
Marabelle A, Le DT, Ascierto PA et al (2020) Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 38:1–10
CAS
Article
Google Scholar
MD Anderson Cancer Center Institute for Personalized Cancer Therapy. https://pct.mdanderson.org
Moscow JA, Fojo T, Schilsky RL (2018) The evidence framework for precision cancer medicine. Nat Rev Clin Oncol 15:183–192
Article
Google Scholar
Quante M (2020) BarrettNET – Risikoevaluation und Prävention von Adenokarzinomen des Ösophagus. In: Forum. Springer, Berlin Heidelberg, S 342–344
Google Scholar
Quante M, Bhagat G, Abrams JA et al (2012) Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett-like metaplasia. Cancer Cell 21(1):36–51. https://doi.org/10.1016/j.ccr.2011.12.004
CAS
Article
PubMed
PubMed Central
Google Scholar
Schmidt M, Ankerst DP, Chen Y et al (2020) Epidemiological risk factors in a comparison of a Barrett Esophagus Registry (BarretNET) and a case control population in Germany. Cancer Prev Res 13(4):377–384. https://doi.org/10.1158/1940-6207.CAPR-19-0474
Article
Google Scholar
Stenzinger A, Van Tilburg CM, Tabatabai G et al (2021) Diagnosis and therapy of tumors with NTRK gene fusion. Pathologe 42:103–115
Article
Google Scholar
Wani S, Falk GW, Post J et al (2011) Risk factors for progression of low-grade dysplasia in patients with Barrett’s esophagus. Gastroenterology 141:1179–1186, 1186.e1
Article
Google Scholar
Westphalen BC, Bokemeyer C, Büttner R et al (2020) Conceptual framework for precision cancer medicine in Germany: consensus statement of the Deutsche Krebshilfe working group ‘Molecular Diagnostics and Therapy. Eur J Cancer 135:1–7
Article
Google Scholar
Wiethaler M, Slotta-Huspenina J, Brandtner A et al (2019) BarrettNET—a prospective registry for risk estimation of patients with Barrett’s esophagus to progress to adenocarcinoma. Dis Esophagus 32(8):doz024. https://doi.org/10.1093/dote/doz024
Article
PubMed
Google Scholar
Annals of Oncology (2021) 32 (suppl_5):S530–S582. https://doi.org/10.1016/annonc/annonc698